UK confirms case of bird flu in poultry in northern England
LONDON (Reuters) -Britain has detected a case of the H5N1 bird flu in poultry in West Yorkshire, northern England, the Department for Environment, Food and Rural Affairs said on Wednesday.
"All poultry on the premises will be humanely culled," a notice on the department's website said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US health chief says Sen. Cassidy promised pick on vaccine panel
WASHINGTON (Reuters) -U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said he told U.S. Senator Bill Cassidy that he would allow Cassidy to pick a candidate for a key panel of vaccine advisers. Cassidy, a Republican, serves as chairman the U.S. Senate Health, Education, Labor, and Pensions Committee. "What I told Senator Cassidy is that I would allow him to put one of his candidates on, which we're going to do," Kennedy said on Thursday during an interview on Fox News' "The Story with Martha MacCallum," referring to the vaccine advisory panel. Kennedy on Wednesday named eight members to serve on the U.S. Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices, which advises the agency on who should get the shots after they are approved by the U.S. Food and Drug Administration, after gutting the panel last week.
Yahoo
an hour ago
- Yahoo
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT. The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. GERMAN BIOTECH CHAMPION The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress. CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros. BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac. The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer. ($1 = 0.8624 euros) (Additional reporting by Christian Kraemer; Editing by Friederike Heine, Jan Harvey and Emelia Sithole-Matarise)
New York Post
2 hours ago
- New York Post
Ozempic use among teens is skyrocketing — and parents are getting a stern warning from experts
It's the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called 'miracle' weight-loss meds are being prescribed to teens in record numbers, with prescriptions among 12- to 17-year-olds jumping 50% in 2024, according to Truveta. Another study from the Evernorth Research Institute, as reported by Reuters, clocked a whopping 68% rise in use among adolescents overall. Advertisement But while slim-down shots like Wegovy may shrink waistlines, some experts say parents should pump the brakes — before turning their kids into pin cushions. Dr. Robert Siegel, a pediatrician at Cincinnati Children's Hospital, didn't mince words, telling the news agency, 'These medications are likely to be needed for a very long time to maintain weight.' He added that 'we only have a relatively short-term experience with them.' Advertisement In other words, we've barely scratched the surface on what these meds might do to growing bodies — and kids could be stuck on them for life. The spike in teen prescriptions comes after Wegovy was approved for adolescents in late 2022. Since then, families desperate to beat back the obesity epidemic — which affects 1 in 4 American teens — have turned to GLP-1 meds in growing numbers. 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system, told Reuters. Advertisement Experts warn we're rolling the dice — these shots could mess with growing bodies, and kids might be stuck jabbing themselves for life. nuzza11 – 'When lifestyle changes alone are insufficient, we need these additional tools.' Still, the new tools come with plenty of fine print. 'The medications may need to be used indefinitely,' Siegel said, noting most pediatricians don't have the training — or equipment — to track long-term effects like muscle loss or developmental delays. Advertisement Novo Nordisk, the maker of Ozempic and Wegovy, insists there's no reason to panic. Slim-down shots might melt fat fast — but docs say teens should ditch the syringes and stick to sweat, not semaglutide, for lasting results. Corbis via Getty Images The company said in a statement that semaglutide 'did not appear to affect growth or pubertal development' in teen clinical trials. 'We are confident in the proven safety and efficacy of our GLP-1 medicines,' Novo added. Eli Lilly, whose drug Zepbound is in trials for teen use, echoed that stance, as per Reuters. 'There has been no evidence to date suggesting impairment in growth or metabolism,' the company said. But that's not enough to calm critics. U.S. Health Secretary Robert F. Kennedy Jr. slammed the trend as a sign of the 'overmedicalization of our kids,' citing a lack of long-term safety data and possible threats to metabolism and development. Advertisement With weight-loss shots looking more like a long-haul commitment than a quick fix, some doctors say teens should focus on old-school strategies before turning to syringes. As The Post previously reported, a survey from digital healthcare platform Tebra found that 37% of young Americans in this age group are planning to ditch the gym and head to the pharmacy instead — turning to Ozempic, Wegovy and other GLP-1 drugs to hit their weight-loss goals. While Gen Z is the most eager to jump on the injection bandwagon, older folks are actually more confident in the drugs' effectiveness — with 72% of baby boomers saying they work better than traditional methods. Still, the craze has a dark side: Some users have turned to shady, even dangerous methods, including counterfeit meds and unprescribed use, triggering new fears about addiction and a lack of proper oversight.
